Company Profile


Suzhou Dingan Technology Co., Ltd. was founded by a core team comprising seasoned experts in the fields of biomedical materials and orthopedic implant devices—among them a Fellow of the Royal Society of Biology, a senior visiting scholar who studied in the United States, a member of the Medical and Surgical Materials and Devices Committee and the Additive Manufacturing Technology Committee of the American Society for Testing and Materials, a member of the Orthopedic Implants Sub‑Technical Committee of the National Technical Committee for Standardization of Surgical Implants and Orthopedic Devices, and a member of the Bone Cement and Injectable Materials Specialized Committee of the Chinese Society for Biomaterials—as well as a Jiangsu Province “333 Project” third‑tier trainee and a leading science and technology entrepreneur in Wujiang City. The company also brings together numerous national-level experts, specialists in materials engineering and clinical orthopedics, and master’s and doctoral degree holders in related disciplines. It is a nationally recognized high‑tech enterprise and a specialized, refined, distinctive, and innovative small‑and‑medium‑sized enterprise in Jiangsu Province, with independent capabilities in the R&D, production, sales, and service of bioactive inorganic materials for surgical implants and high‑end orthopedic implant devices. At present, the company operates five technological innovation service platforms: the Suzhou Biomedical Materials and Advanced Manufacturing Engineering Technology Research Center, the Wujiang District National-Level Expert Workstation, the Jiangsu Province Graduate Workstation, the Soochow University Graduate Workstation, and the Suzhou Postdoctoral Preparatory Workstation. More than 80% of its workforce are technical personnel, including 85% holding bachelor’s, master’s, or doctoral degrees. The company is a member of the American Society for Testing and Materials, the Chinese Society for Biomaterials, the Bone Implant Committee of the Chinese Medical Association, the Jiangsu Provincial Medical Device Industry Technology Innovation Strategic Alliance, and the Jiangsu Provincial Medical Device Flying Inspection Team. Additionally, it has appointed numerous renowned domestic and international experts in biomedical materials and clinical applications as senior advisors.
  The company has long been committed to the industrialization of core technologies and innovative products within the high-end orthopedic implant device industry chain. It has established R&D and production facilities for products including “composite ceramic femoral heads,” “zirconia blocks for all-ceramic dentures,” “calcium phosphate–based bioactive materials and high‑end bone implants,” and “fillers for medical aesthetic minimally invasive procedures.” The company holds manufacturing licenses for Class III medical devices—“Implant Materials and Artificial Organs” (No. 6846)—and Class II medical devices—“Dental Prosthetic Materials” (No. 17‑06)—as well as product registration certificates for “zirconia blocks for all‑ceramic dentures” and ISO 13485 certification for a medical device quality management system (No. 33224M40037R0S). Currently, the company possesses 10 authorized Chinese invention patents, 7 utility model patents, 9 U.S. invention patents, and 2 Indian invention patents; it has also secured international PCT protection for four inventions, with its core technology portfolio for high‑performance artificial joints covering China, the United States, and India. In addition, the company holds nine registered trademarks and twelve copyrights, including ten software copyrights. In 2025, it was successively included in Jiangsu Province’s National Patent Industrialization Demonstration Enterprise Cultivation Database and Suzhou City’s Key Intellectual Property Protection List. The company is certified under an intellectual property compliance management system (No. 404IPA250066R0S), with a scope encompassing the R&D, production, and technical services related to composite ceramic femoral heads, zirconia blocks for all‑ceramic dentures, and bioactive inorganic materials and products for surgical implants. Furthermore, the company’s contributions have been recognized: its achievement, “Key Technologies and Applications for Precision Fabrication of Bioinspired Bone Using Developable Bioceramics,” received the First Prize in the Technical Invention category of the Ministry of Education’s 2019 Higher Education Outstanding Research Achievement Award; and its work on “Key Technologies and Industrial Applications of Hydroxyapatite Whiskers in Dentistry and Orthopedics” was awarded the Second Prize of Yunnan Province’s Science and Technology Progress Award in 2021. Additionally, the company successfully completed two major projects—the National Key R&D Program project titled “Engineering and Clinical Application of a Novel Injectable Nano‑Biomaterial for the Prevention and Treatment of Osteoporosis”—and the Jiangsu Provincial Health Commission’s key clinical frontier project, “Microstructural Regulation and Bone Biological Effects in Two‑Phase Composite Ceramic Repair of Large Segmental Bone Defects,” both of which passed final acceptance.
  In 2023, the company, together with two publicly listed medical device firms, co‑led consortia that successfully secured two projects under the first batch of the “Innovation Challenge” initiative for biomedical materials, organized by the General Office of the Ministry of Industry and Information Technology and the Comprehensive Department of the National Medical Products Administration (Document No. [2023]52, dated September 14, 2023). These projects were titled “Engineering Development and Large‑Scale Application of In‑Situ Composite Calcium Phosphate Materials for Bioactive Artificial Bone” and “Large‑Scale Production and Promotional Application of In‑Situ Synthesized Biphasic Calcium Phosphate Micro/Nanopowders Based on Bioceramic Artificial Bone.” In 2025, the company again took the lead in securing one project—“R&D and Industrialization of Nano‑Hydroxyapatite for Injectable Hydroxyapatite Microsphere Fillers”—and participated in another—“Development and Large‑Scale Application of Hemihydrate Calcium Sulfate‑Based Composite Materials for Bioactive Self‑Curing Bone Cement”—both part of the second batch of the same innovation challenge (Document No. [2025]422, dated November 2, 2025). These achievements underscore the company’s continued recognition at the national level for its technological prowess and innovative capacity, while also demonstrating its capability to drive collaborative R&D across the industry value chain and support the high‑quality development of the biomedical materials sector.
  Over the past fifteen years, the company has developed and manufactured tricalcium phosphate products for surgical implants, which have been certified by the International Organization for Standardization with the international standard product mark. The company has also taken the lead in formulating five group standards: “Tricalcium Phosphate for Surgical Implants (T/CSBM 0027-2022),” “Tetracalcium Phosphate for Surgical Implants (T/CSBM 0028-2022),” “Clinical Application Technical Guidelines for Biodegradable Composite Bone Cement in the Treatment of Osteoporotic Vertebral Compression Fractures (T/ZGCIT 014-2024),” “Performance Evaluation Specifications for Bioactive Artificial Bone Materials (T/CADZ 0039-2025),” and “Safety Performance Evaluation Requirements for Artificial Bone Repair Materials (T/CIET 1649-2025).” Additionally, the company participated in revising three national standards: “Surgical Implants—Hydroxyapatite—Part 3: Chemical Analysis and Characterization of Crystallinity and Phase Purity (GB/T 23101.3-2023),” “Surgical Implants—Hydroxyapatite—Part 4: Determination of Coating Bond Strength (GB/T 23101.4-2023),” and “Surgical Implants—Hydroxyapatite—Part 2: Hydroxyapatite Thermal Spray Coatings (GB 23101.2-2025).” Furthermore, two industry standards have been officially released: “Medical‑Grade β‑Tricalcium Phosphate Powder for Additive Manufacturing (YY/T 1910-2023)” and “Test Methods for Porous Structural Morphology of Surgical Implants (YY/T 1982-2025).” The company has also contributed to the development or revision of nine additional group standards, including “Calcium Sulfate Hemihydrate for Surgical Implants (T/CSBM 0045-2023),” “Test Methods for Porous Structural Characteristics of Calcium Phosphate Bioceramics (T/CSBM 0049-2024),” “Technical Requirements for High‑Performance Ceramic Artificial Joint Materials (T/CIET 1135-2025),” “Technical Requirements for Injectable Hydroxyapatite Microsphere Fillers (T/CIET 1832-2025),” “Quality Requirements for Injectable Nano‑Calcium Hydroxyapatite Microsphere Gels (T/CIET 1559-2025),” “Methods for Determining the Degradation Rate of Biodegradable Bone Repair Scaffolds (T/CADZ 0040-2025),” “Methods for Assessing the Inductive Activity of Bone‑Inducing Materials (T/CIET 1943-2025),” “Application Guidelines for Injectable Materials Used to Repair Alveolar Bone Defects (T/FDSA 0159-2026),” and “Safety Performance Evaluation Requirements for Artificial Bone Repair Materials (T/CIET 1649-2025).” Since 2024, the company has further participated in the formulation or revision of nearly ten additional group standards, such as “Clinical Application Guidelines for Calcium‑Phosphorus‑Based Bioceramics,” “Particle Evaluation for Surgical Implants—Part 1: Collection and Sample Preparation,” and “General Requirements for Injectable Hydroxyapatite Microsphere Gels.” To date, the company has completed the establishment of master documents for 24 key raw materials used in advanced orthopedic implant devices, all of which have been filed and registered with the Medical Device Technical Review Center of the National Medical Products Administration. These include: the master document for plasma‑sprayed hydroxyapatite powder (M2023009-001); the master document for β‑tricalcium phosphate powder used in implant‑grade resin‑based composites (M2023061-000); the master document for nano‑β‑tricalcium phosphate powder for surgical implants (M2024024-000); the master document for submicron β‑tricalcium phosphate powder for surgical implants (M2024055-000); the master document for hydroxyapatite ceramic microspheres for medical aesthetics (M2023072-001); the master document for α‑tricalcium phosphate powder for surgical implants (M2023074-000); the master document for strontium silicate powder for surgical implants (M2023076-000); the master document for hydroxyapatite powder used in implant‑grade resin‑based composites (M2023103-000); the master document for β‑tricalcium phosphate powder for surgical implants (M2024004-000); the master document for hydroxyapatite powder for surgical implants (M2024010-000); the master document for Type II hydroxyapatite microspheres for medical aesthetics (M2024025-000); the master document for submicron hydroxyapatite powder for surgical implants (M2024026-000); the master document for nano‑hydroxyapatite powder for surgical implants (M2024027-000); the master document for 45S5 bioactive glass powder for surgical implants (M2024154-000); the master document for BCP7525 biphasic calcium phosphate powder for surgical implants (M2023105-000); the master document for BCP4555 biphasic calcium phosphate powder for surgical implants (M2024053-000); the master document for BCP7030 biphasic calcium phosphate powder for surgical implants (M2024054-000); the master document for BCP1585 biphasic calcium phosphate powder for surgical implants (M2024171-000); the master document for BCP2575 biphasic calcium phosphate powder for surgical implants (M2024170-000); the master document for BCP2080 biphasic calcium phosphate powder for surgical implants (M2024168-000); and the master document for BCP6040 biphasic calcium phosphate powder for surgical implants (M2024167-000).
  As a champion of “green manufacturing” technology, the company has adopted the corporate mission “For Human Bone Health” and the vision of becoming a pioneer in the innovation of bioactive materials and high‑end surgical implants. Guided by the business philosophy of “Integrity, Innovation, and Professionalism,” it has established industrial footholds across four specialized segments: joint replacement, orthopedics, dentistry, and medical aesthetics. The company consistently focuses on the R&D and commercialization of critical raw materials and core components within the high‑end surgical implant value chain, achieving end‑to‑end coverage of the entire R&D–production–sales process. It currently offers more than a hundred key raw materials and derivative products for high‑end surgical implants—spanning six major product lines, including phosphates, silicates, sulfates, bioactive glasses, functionalized bioactive materials, and bioactive materials for additive manufacturing—and has secured over 200 customers. In the medical aesthetics sector, nearly ten types of high‑end implantable devices—including injectable fillers for minimally invasive cosmetic procedures, biodegradable artificial bone powders, and biodegradable bone cements (Class III)—have completed final design and development. The company has become a qualified supplier to numerous listed companies, industry leaders, prestigious universities and research institutes, and top‑tier Grade‑III hospitals in the field of high‑end surgical implant production. Meanwhile, leveraging five cutting‑edge technology platforms, the company provides comprehensive services such as formulation, modification, physicochemical property evaluation, biological assessment, and animal testing for bioactive inorganic materials and high‑end surgical implants. It also collaborates with universities, research institutes, hospitals, testing organizations, and downstream enterprises to jointly apply for national, provincial, or municipal major and key R&D projects, establishing multiple collaborative consortia dedicated to advancing biomedical materials and high‑end surgical implants, and founding several joint laboratories for the engineering‑scale application of critical raw materials for high‑end surgical implants. Furthermore, the company offers multi‑dimensional, multi‑layered, and multi‑faceted value‑added services, including pre‑project feasibility consulting, implementation plan design, prototype engineering, and customized development of functionalized biomedical materials.
  The company has now become a specialized supplier of high‑end, critical raw materials and derivative products for surgical implantable bioactive inorganic materials, offering a comprehensive product portfolio, mature technologies, and consistently stable quality. It also serves as a key partner and CDMO provider to a broad base of customers in the research, development, manufacturing, and application of innovative high‑end surgical implants.